New York, June 18, 2013 -- Moody's Investors Service commented on Monday's Supreme Court ruling that pharmaceutical companies can be sued to determine whether patent settlements between branded and generic pharmaceutical firms violate antitrust laws. The decision is credit negative for generic pharmaceutical companies as it will increase legal costs and cash flow uncertainty. For our full sector comment go to www.moodys.com.
Vollständigen Artikel bei Moodys lesen